Evidence map›Paper›PMID 22128241›Full record

ArticleMolecular vision2011

Development of a low-pressure microtargeting biolistic device for transfection of retinal explants.

Melissa G Christianson, Donald C Lo

Open access · greenAbstract read
In one paragraph

Article in Molecular vision, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.1field-weighted citation impact, top 56% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Melissa G ChristiansonCenter for Drug Discovery and Department of Neurobiology, Duke University Medical Center, Durham, NC 27704, USA. gottron@neuro.duke.edu
Donald C Lo
Duke University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Biolistic transfection offers a key experimental method for molecular perturbation of bona fide, postmitotic neurons within their native local environment in explanted tissues. However, current, commercially available biolistic devices unavoidably deliver traumatic injury to surface layers of explanted tissues because of helium co-emission with DNA-coated gold particles during the shooting process. This makes such methods unsuitable for use with the delicate tissue layers of the mammalian retina. Here, we report the development of a novel and inexpensive microtargeting biolistic device that avoids the trauma associated with conventional entrainment biolistic methods, permitting rapid and efficient transfection of retinal ganglion cells in the adult mammalian retina without significant damage to their local microenvironment. By using low helium inflow pressures and vacuum diversion to eliminate helium emission during the transfection process, we found that the current method allowed efficient transfection as well as morphological and functional preservation of retinal ganglion cells and their local glial microenvironment in transfected retinal explants from adult rats. The use of an ethanol-gold suspension further supported rapid and extended shooting sequences and reduced shot-to-shot variation during transfection compared to existing tubing-based devices. This new biolistic device should be useful not only in the retina, but also in other tissue explant settings in which preservation of local cellular and tissue integrity is a priority.

Indexed as

BiolisticsTransfectionAnimalsBiomarkersCholera ToxinEthanolFluorescenceGoldHeliumNeurogliaPressureRatsRats, Sprague-DawleyRetinal Ganglion CellsVacuumBiomarkersCholera ToxinEthanolGoldHelium

Identifiers

PMID22128241
PMCPMC3224834
OpenAlexW2110510726

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.